使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
As a reminder, this call is being recorded. Please proceed.
提醒各位,本次電話會議正在錄音。請繼續。
Gretchen Hommrich - Director of IR
Gretchen Hommrich - Director of IR
Good morning, and welcome to Acadia's Fourth Quarter 2018 Conference Call.
各位早安,歡迎參加 Acadia 2018 年第四季電話會議。
To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link.
若今日電話會議中討論任何非 GAAP 財務衡量指標,您亦可在我們網站上,透過投資人(Investors)連結查看昨日新聞稿,找到該指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。
This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2019 and beyond. For this purpose, any statements made during this call that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's fourth quarter news release. And consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. The company undertakes no obligation to update publically any forward-looking statements, whether as a result of new information, future events or otherwise.
本次電話會議可能包含《1995 年私人證券訴訟改革法》所定義之「前瞻性陳述」,其中包括但不限於關於 Acadia 對 2019 年及其後各季度與年度預期財務表現的陳述。就此而言,本次電話會議中任何非歷史事實之陳述,均可能被視為前瞻性陳述。在不限制前述內容之前提下,「相信」、「預期」、「計畫」、「期望」及類似用語旨在識別前瞻性陳述。特此提醒您,這些陳述可能受到多項重要因素影響(其中包括但不限於)Acadia 向美國證券交易委員會提交之文件以及公司第四季新聞稿中所載之因素。因此,實際營運與結果可能與前瞻性陳述中討論之結果存在重大差異。公司不承擔公開更新任何前瞻性陳述之義務,不論係因新資訊、未來事件或其他原因所致。
At this time, for opening remarks, I would like to turn the conference call over to Chief Executive Officer, Debbie Osteen. Please go ahead.
現在,進入開場致詞,我想把電話會議交給執行長 Debbie Osteen。請開始。
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Good morning, and thank you for being with us today for our fourth quarter conference call. I'm very pleased to have this opportunity to speak with you in my first investor call as Chief Executive Officer of Acadia.
各位早安,感謝各位今天參加我們的第四季電話會議。我非常高興能在我擔任 Acadia 執行長後的首次投資人電話會議中與各位交流。
Since arriving at Acadia in late December, I've had the opportunity to talk with many of our employees, referral sources and other key stakeholders, and I am impressed with the strong platform that is in place. We are providing excellent patient care, and our business remains highly relevant in the rapidly evolving health care market.
自我於 12 月下旬加入 Acadia 以來,我有機會與許多員工、轉介來源以及其他關鍵利害關係人交流,我對目前已建立的強大平台印象深刻。我們提供卓越的病患照護,而在快速演變的醫療保健市場中,我們的業務仍具高度相關性。
I'm here today with our president, Brent Turner; Chief Financial Officer, David Duckworth; and other members of our executive management team. David and I each have some remarks about the fourth quarter. I will then close with some additional comments and open the line for your questions.
今天與我一同出席的有總裁 Brent Turner、財務長 David Duckworth,以及其他執行管理團隊成員。David 和我將各自就第四季發表一些看法。之後我會以一些補充評論作結,並開放提問。
Our results for the fourth quarter reflect a consistent revenue improvement we achieved throughout 2018, in spite of some operational challenges, primarily in the U.K. For the fourth quarter of 2018, revenue increased 2.6% and was up 6.2% for 2018.
我們第四季的結果反映出 2018 年全年持續達成的穩健營收改善,儘管面臨一些營運挑戰,主要在英國。2018 年第四季營收成長 2.6%,2018 年全年成長 6.2%。
We have continued to drive organic growth within our existing facilities by expanding our services and adding more bed capacity. Same facility revenue was up 3.8% for the fourth quarter and 5.2% for the full year. Our 3.8% total same facility revenue growth for the fourth quarter included a 2.6% increase in patient days and a 1.2% increase in revenue per patient day.
我們持續透過擴展服務並增加床位容量,在既有機構內推動內生成長。同店(同一機構)營收第四季成長 3.8%,全年成長 5.2%。第四季 3.8% 的同店總營收成長包含病患日(patient days)增加 2.6%,以及每病患日營收增加 1.2%。
In 2018, we continue to look for opportunities to acquire new facilities and enter into strategic partnerships and joint ventures to develop additional behavioral health care facilities.
在 2018 年,我們持續尋找收購新機構的機會,並透過策略合作與合資方式開發更多行為健康照護機構。
During the fourth quarter, we added 243 beds to existing facilities and 651 total beds for the full year, increasing our size and geographic scale and further enhancing our position as a leading provider of behavioral health care services.
第四季我們在既有機構新增 243 張床位,全年合計新增 651 張床位,擴大了我們的規模與地理覆蓋,並進一步強化我們作為行為健康照護服務領先供應商的地位。
U.S. same facility revenue increased 3.5% for the quarter, with a 3.5% increase in patient days. Revenue per patient day was flat compared with the prior year period. U.S. same facility EBITDA margin decreased 130 basis points to 24.9%.
美國同店營收本季成長 3.5%,其中病患日增加 3.5%。每病患日營收與去年同期持平。美國同店 EBITDA 利潤率下降 130 個基點至 24.9%。
We had an accounts receivable adjustment in the fourth quarter that affected these results, and David will provide more detail in his comments.
第四季我們進行了一項應收帳款調整,影響了上述結果,David 將在他的評論中提供更多細節。
For our operations in the U.K., same facility revenue was up 4.4%, consisting of a 1.5% increase in patient days and a 2.8% increase in revenue per patient day.
就英國業務而言,同店營收成長 4.4%,其中病患日增加 1.5%,每病患日營收增加 2.8%。
Same facility EBITDA margin declined 460 basis points to 16.4% for the quarter, consistent with the third quarter and with our expectations for the fourth quarter.
本季同店 EBITDA 利潤率下降 460 個基點至 16.4%,與第三季一致,也符合我們對第四季的預期。
Our U.K. results continue to be impacted by increased operating costs, primarily due to the ongoing nursing and clinical staff shortage and our dependence on higher-cost agency labor. While we expect continued challenges related to the nursing and clinical staff shortage, we remain focused on identifying ways to improve our U.K. operation.
我們英國的結果持續受到營運成本上升的影響,主要原因是護理與臨床人員持續短缺,以及我們對成本較高的派遣人力(agency labor)的依賴。雖然我們預期與護理及臨床人員短缺相關的挑戰仍將持續,但我們仍專注於找出改善英國營運的方法。
Finally, as noted in our press release, we closed 2 previously announced acquisitions in February, Mission Treatment and The Whittier Pavilion. Mission Treatment operates 9 comprehensive treatment centers that provide medication-assisted treatment and counseling for people struggling with opioid addiction in California, Nevada, Arizona and Oklahoma. The Whittier Pavilion is a 71-bed inpatient psychiatric hospital located in Haverhill, Massachusetts. Additionally, we opened 2 de novo facilities in February: Mount Carmel Behavioral Health, a joint venture with 80 beds located in Columbus, Ohio; and Rio Vista Behavioral Health, an 80 bed de novo facility located in El Paso, Texas.
最後,如同我們新聞稿所述,我們已於 2 月完成先前公告的兩項收購:Mission Treatment 與 The Whittier Pavilion。Mission Treatment 經營 9 家綜合治療中心,為在加州、內華達州、亞利桑那州與奧克拉荷馬州受鴉片類藥物成癮所苦的人士提供藥物輔助治療與諮商。The Whittier Pavilion 是一所位於麻薩諸塞州哈弗希爾(Haverhill)的 71 床住院精神科醫院。此外,我們於 2 月新開設兩家新設(de novo)機構:位於俄亥俄州哥倫布(Columbus)的 Mount Carmel Behavioral Health(與合作夥伴合資,80 床);以及位於德州艾爾帕索(El Paso)的 Rio Vista Behavioral Health(80 床的新設機構)。
Now I will turn the call over to David Duckworth to discuss our financial results and guidance in more detail.
接下來我將把電話會議交給 David Duckworth,請他更詳細說明我們的財務結果與指引。
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Thanks, Debbie, and good morning.
謝謝,Debbie,各位早安。
Revenue for the fourth quarter was $743.5 million, an increase of 2.6% compared with $724.5 million for the fourth quarter of 2017.
第四季營收為 7.435 億美元,較 2017 年第四季的 7.245 億美元增加 2.6%。
Net loss attributable to Acadia stockholders was $331.6 million or $3.80 per diluted share for the fourth quarter of 2018 compared with net income of $69.6 million or $0.80 per diluted share for the fourth quarter of 2017.
2018 年第四季歸屬於 Acadia 股東的淨損為 3.316 億美元,或稀釋後每股虧損 3.80 美元;相較之下,2017 年第四季淨利為 6,960 萬美元,或稀釋後每股盈餘 0.80 美元。
In the fourth quarter of 2018, the company completed its goodwill impairment test and recorded a noncash loss on impairment of $337.9 million related to our U.K. operations. This impairment was based on the market challenges, the recent financial performance and revised financial forecast for our U.K. operations.
在 2018 年第四季,公司完成商譽減損測試,並就英國業務認列 3.379 億美元的非現金減損損失。此項減損係基於市場挑戰、近期財務表現以及對英國業務修訂後的財務預測。
Our fourth quarter results also include legal settlements expense of $22.1 million, which primarily relates to the company's billing for lab services in our 7 CTC locations in West Virginia. We were notified of the government's investigation during the third quarter and concluded from our internal review completed in the fourth quarter that our clinics were not following the West Virginia billing requirements. The West Virginia regulations do not permit clinics to bill for lab services performed by a third-party lab. Our clinics utilized the third-party lab according to the billing methodology that was in place prior to Acadia's acquisition of the clinics in 2015. The settlement relates to claim submitted for lab services from 2012 to 2018. We expect the settlement to be finalized in the second quarter.
我們第四季結果亦包含 2,210 萬美元的法律和解費用,主要與公司在西維吉尼亞州 7 個 CTC 據點之實驗室服務收費(billing)相關。我們於第三季收到政府調查通知,並在第四季完成內部審查後得出結論:我們的診所未遵循西維吉尼亞州的收費規定。西維吉尼亞州法規不允許診所就由第三方實驗室執行的實驗室服務進行收費。我們的診所依照 2015 年 Acadia 收購該等診所之前既有的收費方法使用第三方實驗室。本次和解與 2012 年至 2018 年期間提交之實驗室服務請款相關。我們預期該和解將於第二季定案。
Adjusted income attributable to Acadia stockholders for the fourth quarter of 2018 was $40.8 million or $0.47 per diluted share, excluding transaction-related expenses of $24.5 million, debt extinguishment cost of $0.9 million, legal settlements expense of $22.1 million and the loss on impairment of $337.9 million.
2018 年第四季歸屬於 Acadia 股東的調整後淨利為 4,080 萬美元,或每股稀釋後 0.47 美元,不包含與交易相關費用 2,450 萬美元、債務清償成本 90 萬美元、法律和解費用 2,210 萬美元,以及 3.379 億美元的減損損失。
The company's consolidated adjusted EBITDA for the fourth quarter of 2018 was $133.9 million or 18% of revenue.
公司 2018 年第四季合併調整後 EBITDA 為 1.339 億美元,約占營收的 18%。
U.S. same facility revenue was impacted by a fourth quarter 2018 accounts receivable adjustment of approximately $8 million, primarily related to the CTCs and state Medicaid programs in Wisconsin. More specifically, starting in 2016, Wisconsin Medicaid moved from its traditional state Medicaid program, covering medication-assisted treatment services to contracting with 18 managed Medicaid payers. Neither the state, the managed-care organizations nor our clinics were prepared for the different billing requirements implemented by each payer. For 2018, we have successfully implemented processes, under which we billed and collected for our services on a current basis. However, we've been working with the state to review claims that accumulated during the first 2 years of the transition in 2016 and 2017.
美國同院所營收受到 2018 年第四季應收帳款調整約 800 萬美元的影響,主要與威斯康辛州的 CTCs 及州 Medicaid 計畫有關。更具體而言,自 2016 年起,威斯康辛州 Medicaid 從其傳統的州 Medicaid 計畫(涵蓋藥物輔助治療服務)轉為與 18 家受管理的 Medicaid 付款方簽約。無論是州政府、受管理照護組織,或是我們的診所,都未能為各付款方所實施的不同帳單要求做好準備。在 2018 年,我們已成功導入流程,使我們能以即時基礎對服務進行開立帳單並收款。然而,我們一直與州政府合作,審查在 2016 與 2017 年轉換最初兩年期間累積的理賠申請。
While the review and collection are ongoing, we determined during the fourth quarter that an $8 million adjustment was appropriate based on the status of the discussions. Excluding this adjustment, U.S. same facility revenue increased 5.3% with a 1.7% increase in revenue per patient day, and U.S. same facility EBITDA margin stayed consistent at 26.2%.
在審查與收款仍在進行之際,我們於第四季依據討論進度判定,進行 800 萬美元的調整是適當的。排除此項調整後,美國同院所營收成長 5.3%,其中每病人日營收成長 1.7%,而美國同院所 EBITDA 利潤率維持在 26.2% 不變。
Acadia's operating cash flows from continuing operations were $416.6 million for 2018 compared with $401.3 million last year, an increase of 3.8%.
Acadia 2018 年持續營運活動所產生的營運現金流為 4.166 億美元,較去年的 4.013 億美元增加 3.8%。
We recently amended our senior secured credit facility to modify certain definitions and provide increased flexibility in terms of our financial covenants. As of December 31, 2018, the company had significant availability under our $500 million revolving credit facility, and our leverage ratio was approximately 5.3.
我們近期修訂了優先擔保信貸融資安排,以調整若干定義,並在財務契約條款方面提供更高的彈性。截至 2018 年 12 月 31 日,公司在 5 億美元循環信貸融資項下仍有可觀的可用額度,而我們的槓桿比率約為 5.3。
Turning to our financial guidance, and as announced in our news release, our guidance for the full year 2019 and for the first quarter of 2019 is as follows: revenue for 2019 in a range of $3.15 billion to $3.2 billion; adjusted EBITDA for 2019 in a range of $610 million to $630 million; adjusted earnings per diluted share for 2019 in a range of $2.15 to $2.30; and adjusted earnings per diluted share for the first quarter of 2019 in a range of $0.35 to $0.36.
接著談我們的財務指引。如同我們在新聞稿中所宣布,我們對 2019 全年及 2019 年第一季的指引如下:2019 年營收介於 31.5 億至 32.0 億美元;2019 年調整後 EBITDA 介於 6.10 億至 6.30 億美元;2019 年每股稀釋後調整後盈餘介於 2.15 至 2.30 美元;以及 2019 年第一季每股稀釋後調整後盈餘介於 0.35 至 0.36 美元。
Our guidance includes the following forecast for nonoperating cost for 2019: interest expense of approximately $195 million; depreciation expense of approximately $170 million; stock compensation expense of approximately $26 million; an exchange rate of $1.30 per British pound sterling; and an effective tax rate of approximately 16%.
我們的指引包含以下 2019 年非營運成本預測:利息費用約 1.95 億美元;折舊費用約 1.70 億美元;股票酬勞費用約 2,600 萬美元;匯率為每 1 英鎊兌 1.30 美元;以及有效稅率約 16%。
This concludes my prepared remarks this morning, I'll turn it back over to Debbie for some final comments.
以上為我今天上午的準備發言,接下來我把時間交還給 Debbie 做最後的幾點說明。
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Thanks, David. Now that we have covered the results, and before we take your questions, I would like to take some time this morning to talk about some initial impressions and my plans to address our future strategy.
謝謝你,David。現在我們已經說明了業績,在回答各位提問之前,我想利用今天上午的時間談談一些初步觀察,以及我為因應未來策略所擬定的計畫。
I joined the company in December because I saw the opportunity to lead a company with a history of driving shareholder value and delivering the highest levels of patient quality. Since joining, I've been working to better understand the opportunities and challenges ahead for Acadia. I'm very impressed with the team at the corporate level as well as the operations team supporting the facilities.
我在 12 月加入公司,因為我看到了帶領一家具有提升股東價值歷史、並提供最高水準病患照護品質的公司之機會。加入以來,我一直在努力更深入了解 Acadia 未來面臨的機會與挑戰。我對公司總部團隊以及支援各院所的營運團隊印象非常深刻。
Though my conversations with employees and stakeholders have reinforced my belief in Acadia's strong position, I recognize that there is more work for our team to do. I have heard candid feedback and take it seriously. I am closely evaluating all aspects of our business to see where we have opportunities, and I'm also looking for improvements we can make to deliver better performance.
雖然我與員工及利害關係人的對話更強化了我對 Acadia 強勢地位的信心,但我也認知到團隊仍有更多工作要做。我聽到了坦率的回饋,並且非常重視。我正在密切評估我們業務的各個面向,以找出我們的機會所在,同時也在尋求可改善之處,以帶來更佳的表現。
My highest priority is to drive a significant increase in shareholder value over time by developing and executing strategies that will leverage our strength and provide excellent care to the many patients that come to Acadia facilities for help. Although, as you would expect, I'm still working on evaluating our business, I expect to provide my views on strategy and future direction in May. In the meantime, I look forward to engaging with you over the coming weeks.
我最高的優先事項,是透過制定並執行能發揮我們優勢的策略,並為前來 Acadia 院所尋求協助的眾多病患提供卓越照護,從而在時間推移中大幅提升股東價值。雖然如各位所預期,我仍在評估我們的業務,但我預計在 5 月提出我對策略與未來方向的看法。在此期間,我期待在接下來幾週與各位交流。
I will now ask April to open the floor for your questions.
我現在請 April 開放現場讓各位提問。
Operator
Operator
(Operator Instructions) And we'll take our first question from A.J. Rice with Crédit Suisse.
(接線員指示) 我們將先接聽來自瑞士信貸 A.J. Rice 的第一個問題。
Albert J. William Rice - Research Analyst
Albert J. William Rice - Research Analyst
Best wishes, Debbie, on the new role. First, the -- first question, I don't know if you've had a chance to develop an opinion about this yet, but Acadia is consistently, in the U.S. operations, delivered mid- to sometimes even high single-digit comparable facility revenue growth. I know that seems not to be able to be what the other public peers have done, as you know. A little lower than that. If you have developed a view, is it a service mix thing? Is it a geographic mix? Is it maybe the labor pipeline? Have you been able to develop a view as to they've been able to do that, and you did it this quarter of 5.3% same-store growth? And do you think that sort of mid-single-digit type of growth rate on the U.S. operations is a reasonable long-term target, realizing quarter-to-quarter could fluctuate?
Debbie,祝賀你擔任新職務一切順利。首先,第一個——第一個問題,我不確定你是否已經有機會形成看法,但 Acadia 在美國業務方面,一直能夠交出中到有時甚至偏高的個位數同院所營收成長。如你所知,這似乎是其他上市同業難以做到的。他們的表現略低一些。如果你已形成看法,這是服務組合的因素嗎?是地理分布組合嗎?或可能是人力供給管道?你是否能形成一個看法,為何他們能做到這點,而你們本季也做到了 5.3% 的同店成長?你是否認為,美國業務這種中個位數的成長率,作為長期目標是合理的——當然也理解每季之間可能會有波動?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
A.J., I think you've mentioned a couple of the key things that I've been able to see since I joined the company. I think there's a very strong growth platform here. There's a real diversification of services across geography that, I think, has been very helpful and very strong to generate the growth. I think the team that I've met and the processes I've seen have really shown the ability to respond to opportunities. And I think that's just the way the facilities are laid out and configured, I think they really have very good relationships with their payers, and that's helped, as well as doing a good job, frankly, with the staffing and physician challenges that the industry faces.
A.J.,我想你提到的幾點,正是我加入公司以來所能看到的一些關鍵因素。我認為這裡有非常強的成長平台。我認為跨地理區域的服務多元化,對於帶動成長非常有幫助且相當強勁。我所接觸到的團隊以及我看到的流程,確實展現出回應機會的能力。我也認為,院所的布局與配置方式,使其與付款方維持非常良好的關係,這有所助益;此外,坦白說,在產業面臨的人力配置與醫師挑戰上,他們也做得很好。
Albert J. William Rice - Research Analyst
Albert J. William Rice - Research Analyst
Okay. And then my follow-up question, I guess -- or my other question would be that I know there was discussion in the fourth quarter about there being potentially 20 or 30 facilities in the U.K. that were operating around breakeven, plus or minus, a little bit. And then maybe, the performance over there could be significantly enhanced if there was a more focused look at either repositioning those, eliminating those, closing those even for real estate value. I know you took a big charge related to the U.K. operations with the fourth quarter. Is that a prelude to doing something on those targeted facilities? Any comment about how much taking that charge might help the operating margins in the U.K. going forward?
好的。接著我的追問——或另一個問題是,我知道第四季曾討論到英國可能有 20 或 30 家院所的營運大致在損益兩平附近,上下略有差異。而且如果能更聚焦地檢視,透過重新定位、淘汰,甚至為了不動產價值而關閉,當地的表現或許能顯著提升。我知道你們在第四季針對英國業務計提了一筆很大的費用。那是否是針對這些目標院所採取行動的前奏?另外,關於計提這筆費用,對於未來英國營運利潤率可能帶來多少幫助,你有任何評論嗎?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Well, A.J., 9 sites in the U.K. closed in 2018. There wasn't a lot of financial impact. But I recently visited there, and I think the team is looking closely at the facilities that might be appropriate for closure. But I think they're also looking at the possibility of facilities that are closed being retooled into higher-revenue services and changing the service mix. So I think that evaluation has been ongoing and it continues.
嗯,A.J.,英國在2018年關閉了9個據點。財務影響不大。但我最近去那邊拜訪,我認為團隊正在仔細檢視哪些設施可能適合關閉。不過我也認為,他們同時在評估已關閉的設施是否有可能重新調整用途,轉型為更高營收的服務,並改變服務組合。所以我認為這項評估一直在進行,而且仍會持續。
Operator
Operator
And we'll take our next question from Brian Tanquilut with Jefferies.
接下來我們將請 Jefferies 的 Brian Tanquilut 提問。
Brian Gil Tanquilut - Equity Analyst
Brian Gil Tanquilut - Equity Analyst
And Deb, welcome to Acadia. So I guess, my first question is just from a guidance perspective, maybe for David or Brent. Can you guys walk us through how you would bridge from the Q4 numbers, or think about it as a run rate, to the guidance for 2019 and then the ramp that you would assume given the Q1 guidance that you've given?
Deb,歡迎加入 Acadia。所以我想,我的第一個問題是從財測指引的角度,可能請 David 或 Brent 回答。你們能否帶我們梳理一下,如何從第四季的數字(或把它視為一個運行水準 run rate)銜接到2019年的指引,以及再結合你們給出的第一季指引,應該如何假設後續的爬坡(ramp)?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Brian, this is David. We do see a number of factors that are impacting our guidance for the first quarter. And then as you look at the rest of the year, these factors also play a role in the improvement that we see in our U.S. and U.K. operations. So let me walk through those factors. First, in the U.K., we do have an EBITDA margin in the second half of 2018 of just under 15%. We do see that continuing in the first quarter, but think with the number of initiatives that, that will improve. The occupancy as well as rate increases and other initiatives, we think, will play a role in the improvement in the U.K. operations. But in the first quarter, and really the first part of the year, we do see a lower run rate for our U.K. operations in terms of the margin. And then in the U.S., we have number of beds that have been brought online, 6 de novo facilities going back to the fourth quarter of 2017, all the way through the 2 that have opened in February. So we have a number of beds in de novo facilities that have been ramping. We're very optimistic about the contribution from those facilities, but we do see a first quarter impact from those facilities, especially with the 2 that have opened this quarter. So we do have around $2.5 million of losses that are affecting the first quarter number from the de novo facilities, but see at the end of the year that there's going to be positive EBITDA contribution from those facilities. Additionally, in the U.S., we had 2 facilities that closed in the fourth quarter. In addition, we had one facility closing in the first quarter of this year. There are some losses incurred at those facilities in the fourth quarter as well as the first quarter and that's about $1.5 million per quarter of losses. We think that the wind down of those operations will be complete and, as we move past the first quarter, that there will be contribution from those facilities. So in terms of the operating contribution, the new beds in the U.S. will improve and will be more reflective of the improvement in the last 9 months of the year. And then from a nonoperating cost, we did provide the guidance around interest and depreciation and the stock comp. There is about a $0.07 impact or so just year-over-year in the first quarter that's impacting the results, and that also moderates and has less of an impact throughout the year.
Brian,我是 David。我們確實看到有多項因素正在影響我們對第一季的指引。而當你看全年其餘時間時,這些因素也會在我們看到美國與英國營運改善的過程中扮演角色。我先帶你逐一說明這些因素。首先,在英國,我們2018年下半年的 EBITDA 利潤率略低於15%。我們預期第一季會延續這個水準,但也認為隨著多項措施推進,利潤率會改善。我們認為入住率提升、價格上調以及其他措施,將有助於英國營運的改善。但在第一季,甚至更廣義地說在今年前段,我們確實看到英國營運在利潤率方面的 run rate 較低。接著在美國,我們有一些床位已經上線:自2017年第四季起共有6家 de novo(新設)機構,直到今年2月又有2家開業。因此,我們有不少位於 de novo 機構的床位正在爬坡。我們對這些機構的貢獻非常樂觀,但確實看到第一季會受到影響,尤其是本季新開的那2家。因此,de novo 機構約有250萬美元的虧損影響第一季數字,但我們預期到年底這些機構將帶來正向的 EBITDA 貢獻。此外,在美國,我們在第四季關閉了2家機構。另外,今年第一季也關閉了1家機構。這些機構在第四季及第一季都產生了一些虧損,約每季150萬美元的虧損。我們認為這些營運的收尾將會完成,且當我們度過第一季後,這些機構將會帶來貢獻。因此,就營運貢獻而言,美國新增床位將會改善,並且更能反映在今年後9個月的改善幅度。另外在非營運成本方面,我們也提供了利息、折舊與股票酬勞的指引。第一季相較去年同期約有0.07美元左右的影響,這會壓抑結果,而這個影響在全年會趨於緩和、影響也會變小。
Brian Gil Tanquilut - Equity Analyst
Brian Gil Tanquilut - Equity Analyst
All right. Got it. And then my follow-up, I'd like to hear about growth initiatives. I noticed that you've stepped down the target number of bed openings for this year. And obviously, you came in at the 600 range for 2018. So Deb, is that sort of the new way we should be thinking about growth? And what's your perspective on ratching this down a little bit from the previous targets of about 800 or so?
好的。了解。那我的追問想聽聽成長計畫。我注意到你們下調了今年目標開放床位的數量。而且很明顯,2018年你們大約落在600張左右。所以 Deb,這是否是我們今後應該用來思考成長的新方式?你對於把目標從先前大約800張左右下調一些,有什麼看法?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
I'd think, Brian, that we really try to identify what we think makes sense as far as bed additions to our existing facilities. So a lot of the bed growth that we are projecting in 2019 relates to existing facilities. We aren't planning to open any additional de novos for the year. We, I think, just look and preview where we think those beds can be added. We're going to take each year really independently and look at what we think those opportunities look like. So I don't think we've really guided those down that -- in a way that's going to continue, but really just try to project what we think makes sense for this coming year.
Brian,我認為我們確實會努力辨識,對於在既有設施增加床位而言,什麼樣的規模是合理的。因此,我們在2019年所預估的床位成長,很多是來自既有設施。我們今年不打算再開任何額外的 de novo(新設)機構。我想我們只是檢視並預判哪些地方適合新增這些床位。我們會把每一年相對獨立地看待,並評估我們認為有哪些機會。所以我不認為我們是以一種會持續下調的方式去下修指引,而是單純試著預估我們認為對接下來這一年合理的規劃。
Operator
Operator
And we'll take our next question from John Ransom with Raymond James.
接下來我們將請 Raymond James 的 John Ransom 提問。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
And a warm welcome, Deb. A number of people who watch your company question whether the U.K. asset is, long term, a strategic asset for the company. So in your strategic review process, is potentially divesting the U.K. part of something that you're still thinking about? Or have you ruled that out at this point?
Deb,熱烈歡迎。有不少關注你們公司的投資人質疑,英國資產從長期來看是否仍是公司具有策略性的資產。所以在你們的策略檢視流程中,是否仍在考慮可能處分(divest)英國業務?還是你們目前已經排除這個選項?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Well, John, I think we haven't really ruled anything out because we really want to do a thorough and thoughtful assessment. And part of that will be for the U.S. as well as the U.K. So we're going to evaluate all aspects of the business as well as potential strategies for the U.S. and the U.K. And I will be talking hopefully more about, I think, the strategy in a more concrete way in May.
John,我想我們其實沒有把任何選項排除,因為我們希望做一個全面且審慎的評估。而其中一部分也會涵蓋美國以及英國。因此,我們會評估業務的各個面向,以及美國與英國可能的策略。我也希望能在5月更具體地談談策略。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
Okay. And secondly, it's not clear, at least to me, if we assume labor shortages are structural in the U.K. and the state's going to pay what the state's going to pay, what are the levers that you guys are going to pull this year to try to improve the margin, which, as you guided, was down almost 500 bps year-over-year. So what can you do other than just shutting down facilities that don't make money?
好的。第二個問題,至少對我來說還不太清楚:如果我們假設英國的勞動力短缺是結構性的,而政府(州)能支付的費用就是那樣,那你們今年打算透過哪些槓桿來改善利潤率?因為如你們所指引,利潤率年對年下滑了將近500個基點。所以除了關閉不賺錢的設施之外,你們還能做什麼?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
I think the team in the U.K. is really focused on a few areas. One is improving the occupancy at the facilities that are open now. They brought a number of beds that were retooled last year in offline back online. Another area, obviously, that needs focus, and I think they've got some plans around, is really reducing the agency spend by bringing in more permanent employees, nurses and workers. And then the other area is just around the fees and trying to work in collaboration with NHS to present the increased costs that are part of the environment there with the national living wage and other areas. And so I think their idea and plan is to focus around those and really trying to improve capacity rather than adding a lot of additional beds, really improving the pipeline of patients coming into the existing facilities.
我認為英國團隊主要聚焦在幾個領域。第一是提升目前仍在營運的設施之入住率。他們把去年重新調整用途、曾經下線(offline)的部分床位,重新上線。另一個顯然需要聚焦的領域,而且我認為他們也有一些計畫,是透過引進更多正式員工(永久員工),包括護理師與照護人員,來降低對派遣人力(agency)的支出。再來一個領域是費率,並嘗試與 NHS 合作,反映當地環境中的成本上升,包括全國生活工資(national living wage)以及其他因素所帶來的增加成本。因此我認為他們的想法與計畫是聚焦在這些面向,並且更著重於提升產能利用,而不是新增大量床位;也就是改善既有設施的病患導入管線。
Operator
Operator
And we'll take our next question from Ralph Giacobbe with Citi.
接下來我們將接聽花旗(Citi)Ralph Giacobbe 的提問。
Ralph Giacobbe - Director
Ralph Giacobbe - Director
The business has obviously faced margin pressure for a while now and, in some cases, even despite mid- or high single-digit revenue growth. So I guess, the question is, do you have any sense of sort of margin targets in the U.S. and in the U.K? And what kind of organic top line you think is needed to sort of sustain a baseline level?
這項業務顯然已經面臨一段時間的利潤率壓力了,而且在某些情況下,即使營收有中個位數或高個位數的成長也是如此。所以我想問的是,你們對美國和英國的利潤率目標是否有任何概念?以及你們認為需要什麼樣的有機營收成長,才能在某種程度上維持一個基準水準?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes. Ralph, this is David. We do have a targeted margin improvement in the U.K. and that's compared to the second half of 2018. There is top line revenue growth of between 3% and 5% that will support some margin improvement. That's just as occupancy improves in the U.K., the beds that have been retooled come back online, we see that 3.5% revenue growth driving some margin improvement with a target of around 16% for the U.K. on the margin. In the revenue -- for revenue in the U.S., we do have a 5% to 6% revenue growth target that should support some margin improvement in our U.S. operations as well. So we -- we're optimistic about the beds that have come online. The number of beds coming online in 2019 is also a strong number that, we think, supports continued U.S. revenue growth.
是的。Ralph,我是 David。我們在英國確實有一個目標性的利潤率改善,這是相較於 2018 年下半年。營收年增介於 3% 到 5% 之間,將支持一定程度的利潤率改善。也就是說,隨著英國入住率改善、已重新調整的床位重新上線,我們看到 3.5% 的營收成長帶動一些利潤率改善,英國的利潤率目標大約在 16% 左右。至於美國的營收——在美國方面,我們有 5% 到 6% 的營收成長目標,這也應能支持我們美國營運的利潤率改善。所以我們——我們對已上線的床位感到樂觀。2019 年上線的床位數量也相當可觀,我們認為這支持美國營收持續成長。
Ralph Giacobbe - Director
Ralph Giacobbe - Director
Okay. Great. That's very helpful. And then just a follow-up. Can you maybe help me on sort of the amendment in the credit facility and how much flexibility it gives you? And then you mentioned deals in 1Q. How active will you be versus managing leverage and if there is any update on the leverage target at this point as well?
好的。很好。這非常有幫助。接著追問一下。你能否說明一下信貸融資安排(credit facility)的修訂,以及它為你們帶來多少彈性?另外你提到第一季有交易。在管理槓桿的同時,你們會有多積極?以及目前槓桿目標是否有任何更新?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Sure. We continue to have a leverage target of 5x. I think that we'd get there at the end-of-the-year just from the earnings growth that we expect. We did -- as we look at the step-downs that were in our existing credit agreement, we did want to take out some of the -- just risk there and create a better cushion for us throughout the year and add more flexibility to what -- how we can access our credit. And so we did add about half a turn. The covenants were stepping down on a total leverage basis to 5.75 and then to 5.5 at the end of the year. And we've added about a half a turn to that and now stepped down within our covenants to 6x at the end of 2019. There's a similar cushion that was added for the remaining term of the credit facility. There were also some definitional adjustments that were made that are positive for us, mainly around an add-back to EBITDA for any noncash items, such as an impairment, whereas in the past agreement, that was a limited, noncash add-back. So I'm feeling positive about the amendments that were made to the credit facility and the support from our debt lenders there.
當然。我們仍維持 5 倍的槓桿目標。我認為我們會在年底達到,主要是因為我們預期的獲利成長。我們確實——在檢視現有信貸協議中的逐步下調條款(step-downs)時,我們希望移除其中一些——風險,並在全年為我們建立更好的緩衝,同時增加我們在——如何動用信貸方面的彈性。因此我們增加了大約半圈(half a turn)。原本契約條款是在總槓桿基礎上逐步下調至 5.75,然後在年底降至 5.5。我們在此基礎上增加了大約半圈,現在契約中的逐步下調在 2019 年底為 6 倍。在信貸融資剩餘期限內,也加入了類似的緩衝。此外也做了一些定義上的調整,對我們是正面的,主要是針對 EBITDA 的加回(add-back)可涵蓋任何非現金項目,例如減損;而在先前的協議中,這類非現金加回是受限的。因此我對這次信貸融資修訂以及我們債權人提供的支持感到正面。
Operator
Operator
And we'll take our next question from Whit Mayo with UBS.
接下來我們將接聽瑞銀(UBS)Whit Mayo 的提問。
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Debbie, maybe not a terribly fair question, but once we get to May and you have a better sense of what the go-forward strategy is going to be, do you envision the implementation of that strategy to be terribly different? Do we need to be prepared for an investment period? Is there a major pivot in strategy, no pivot in strategy? And then maybe what do you see as the clear, like, 2 areas today as an opportunity for improvement within the organization?
Debbie,這可能不是個很公平的問題,但等到 5 月、你對未來的策略有更清楚的掌握之後,你是否預期該策略的落實會有很大的不同?我們是否需要為一段投資期做準備?策略會有重大轉向、還是不會轉向?另外,你認為目前組織內最明確、像是兩個可以改善的機會領域是什麼?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Whit, I think I want to complete our assessment and I want to be very thoughtful about it before I start talking about changes and direction. As I said earlier, I think there's a very strong platform here, but I do think there's opportunity for improvement in both the U.S. and, certainly, the U.K. So I'll be able to discuss more about that in May.
Whit,我想先完成我們的評估,而且在開始談變革與方向之前,我希望非常審慎地思考。如我先前所說,我認為這裡有一個非常強的基礎平台,但我也確實認為美國與——當然——英國都有改善的機會。所以我會在 5 月能夠再多談一些。
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Okay. I had to try. David, of the AR write-down, can you maybe give a little more color around how much was really out of period dating back to 2016? I think we have an understanding of what happened. Did you write off everything? Is there anything left that is at risk going forward? And is there an opportunity, potentially, to pick up some more of that as the year plays out? I'm just trying to think about the right jumping off point for the year.
好的。我得試試看。David,關於應收帳款(AR)減記,你能否再多提供一些細節,說明其中有多少其實是跨期、可追溯到 2016 年的?我想我們大致理解發生了什麼。你們是否把所有的都沖銷了?未來是否還有任何部分仍存在風險?以及隨著今年進行,是否可能有機會再收回一些?我只是想思考今年的合理起點。
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Right. We do attribute all of the $8 million adjustment to prior years and to 2016 and 2017, specifically. We do think the reserve that we've put in place is appropriate and, therefore, not really reflecting any opportunity, in our view, for there to be much upside there. We -- we're going through the final discussions around the amount that we expect to collect for those 2 years, but feel like the reserve we established was appropriate.
是的。我們將這 800 萬美元的調整全部歸因於前幾年,具體而言是 2016 年與 2017 年。我們認為我們已提列的備抵是適當的,因此在我們看來,並不真正反映那裡會有太多上行空間。我們——我們正在就這兩年預期可收回的金額進行最後討論,但我們覺得所建立的備抵是適當的。
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Okay. Maybe one last one just back to the startup losses. I think you said, David, you expect maybe $2.5 million of losses in the first quarter. Looking at your disclosures, it looks like you may have had about $12 million in the past 12 months. So I'm just trying to get a sense of how quickly that $2.5 million reverses itself in the first quarter and what you're expecting for the full year contribution in 2019.
好的。最後一個問題,回到新設據點的啟動虧損(startup losses)。我想你說過,David,你預期第一季可能有 250 萬美元的虧損。看你們的揭露,過去 12 個月似乎約有 1,200 萬美元。所以我想了解第一季的 250 萬美元會多快反轉,以及你們對 2019 年全年貢獻的預期是什麼。
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Right. We do expect $2.5 million of losses in the first quarter. And keep in mind, we have 2 facilities that are currently brand new. Going through the licensing survey process will take the next 2 to 3 months just to focus on that. And we have a number of other facilities that have now been opened more than a year in that 6 to 9-month period, where we expect to get very close to breakeven and positive results. And so the way we see it playing out throughout the year is probably another $1 million or so of losses in the second quarter, but expect a breakeven and even some positive contribution in the second half of the year. And hopefully, EBITDA in the second half of the year from those 6 facilities will be around $2 million in those 6 months. So on a year-over-year basis, with the negative impact in 2018, we expect to be about $1 million to $2 million loss in 2019.
是的。我們確實預期第一季會有 250 萬美元的虧損。而且請記得,我們目前有 2 家機構是全新開設的。接下來 2 到 3 個月將進入許可(licensing)稽核流程,我們會專注在這件事上。另外我們還有一些其他機構已開業超過一年,處於那個 6 到 9 個月的區間,我們預期會非常接近損益兩平並出現正向結果。因此我們看今年的走勢,第二季可能還會有約 100 萬美元左右的虧損,但預期下半年可達損益兩平,甚至有一些正向貢獻。並且希望這 6 家機構在下半年 6 個月的 EBITDA 約為 200 萬美元。所以以年對年來看,考量 2018 年的負面影響,我們預期 2019 年約為 100 萬到 200 萬美元的虧損。
Operator
Operator
We'll take our next question from Frank Morgan with RBC Capital Markets.
接下來我們將接聽 RBC 資本市場(RBC Capital Markets)Frank Morgan 的提問。
Frank George Morgan - MD of Healthcare Services Equity Research
Frank George Morgan - MD of Healthcare Services Equity Research
I'd like to go back to the -- A.J.'s original question, looking and comparing and contrasting your company to your former employer. There's always been a lot of discussion around some glaring differences in what is otherwise seems to be a -- the same business. But could you give us some knowledge and some insight into what you're seeing specifically in your labor markets, and I know that labor has always been called out a shortage issue more for your neighbors. And then also on the payer mix side, are you seeing as much of this shift from traditional Medicare to managed -- I'm sorry, traditional Medicaid to managed Medicaid? And then the third point, it always seems to come up is a difference related to this differential you're seeing in length of stay. Are you seeing -- what would you attribute the difference is to -- in terms of length of stay pressure? That's my first question.
我想回到——A.J. 最初的問題,也就是把貴公司與您先前的雇主做比較與對照。一直以來,外界對於一些明顯差異有很多討論,因為在其他方面看起來似乎是——同一門生意。但您能否就您在勞動力市場上具體看到的情況,提供一些知識與洞見?我也知道,勞動力一直被點名為短缺問題,尤其是對你們的鄰居而言。另外在付款方組合(payer mix)方面,您是否也看到從傳統——抱歉,從傳統 Medicaid 轉向管理式 Medicaid 的這種轉移?第三點也總是會被提到,就是您們在住院天數(length of stay)上看到的差異。您是否看到——您會把住院天數壓力方面的差異歸因於什麼——就住院天數而言?這是我的第一個問題。
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Okay, I'll take the salary wage piece first, Frank. I think that the distribution of the Acadia facilities is geographically different than my neighbor, UHS. I think that when you look at where the facilities are and also some of the more competitive markets that -- where a lot of beds have been built, a lot of competition for staff and physicians, Acadia is not in some of those markets. They clearly have a few that they're in, but I think it's really a different distribution. And also the service lines that Acadia has are different than UHS. I think they are more evenly distributed across substance use, the acute behavioral, certainly with the CTC portfolio as well and the RTC. So it's really not a direct comparison that can be made because it's different geography and then different service lines in the business. As far as the Medicaid movement, we really haven't seen that movement in the markets in states that Acadia is in. We don't have an overly concentrated presence in any of the states that, I think, have been called out by UHS. And so that puts us in a different position. The length of stay for Acadia is very stable. It's 9.1 days, and it's consistent from '17 to '18. So there's not been that pressure from the managed Medicaid in any meaningful way. We have pockets where, clearly, we see that, but not in a meaningful way to Acadia. I think that answered everything, Frank.
好的,Frank,我先談薪資與工資這一塊。我認為 Acadia 的設施分布在地理上與我的鄰居 UHS 不同。我認為,當你看設施所在位置,以及一些競爭更激烈的市場——那裡新建了很多床位、對員工與醫師的競爭也很激烈——Acadia 並不在其中一些市場。他們當然有少數市場有涉足,但我認為整體分布確實不同。此外,Acadia 的服務線也與 UHS 不同。我認為他們在物質使用(substance use)、急性精神/行為健康(acute behavioral)之間的分布更平均,當然也包括 CTC 組合以及 RTC。因此這並不是可以直接比較的情況,因為地理分布不同,而且業務中的服務線也不同。至於 Medicaid 的轉變,我們在 Acadia 所在州的市場中,確實沒有看到那樣的轉變。我們在任何一個州都沒有過度集中的布局;我想 UHS 點名的那些州也是如此。因此我們所處的位置不同。Acadia 的住院天數非常穩定。是 9.1 天,且從 2017 年到 2018 年都一致。因此,管理式 Medicaid 並未以任何有意義的方式帶來那種壓力。我們確實有一些區域會看到那種情況,但對 Acadia 整體而言並不顯著。我想這回答了所有問題,Frank。
Frank George Morgan - MD of Healthcare Services Equity Research
Frank George Morgan - MD of Healthcare Services Equity Research
Yes. And maybe just one more as my follow-up. On that topic of managed Medicaid, would you, by chance, of your Medicaid book, would you know the percentage that's actually in managed Medicaid today?
是的。我再追問一個。就管理式 Medicaid 這個主題,請問在你們的 Medicaid 業務中,您是否知道目前實際屬於管理式 Medicaid 的比例是多少?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes. Frank, this is David. I'll take that one. We do already see managed Medicaid within what we report as Medicaid. The last time we looked, I think it was around 2/3 of our Medicaid was with a managed Medicaid payer in the U.S.
是的。Frank,我是 David。這題我來回答。在我們所揭露為 Medicaid 的項目中,其實已經包含管理式 Medicaid。上一次我們檢視時,我記得在美國,我們的 Medicaid 大約有 2/3 是由管理式 Medicaid 付款方承保。
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
And I'll just add, Frank, I think one difference here, too, is that Acadia is in states that have already gone managed. And so there hasn't been as much of the conversion that's taking place, moving from straight Medicaid to managed as there has been in some of the states that UHS is in.
我再補充一下,Frank,我認為這裡另一個差異是,Acadia 所在的州多數已經轉為管理式。因此,相較於 UHS 所在的一些州,從傳統 Medicaid 轉為管理式 Medicaid 的轉換幅度就沒有那麼大。
Operator
Operator
We'll take our next question from Kevin Fischbeck with Bank of America.
下一題我們請美國銀行(Bank of America)的 Kevin Fischbeck。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
Just want to clarify, I think you said 5% to 6% growth in the U.S. Obviously, you did some deals there. Is that a same store number? Or is that a total revenue number?
我想確認一下,我記得你說美國業務成長 5% 到 6%。顯然你們也做了一些交易。那是同店(same store)數字嗎?還是總營收的數字?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Kevin, that is a -- that's an organic number, the 5% to 6%. There would be some additional contribution from the de novo facilities and as well as the 2 acquisitions that we announced, but also some impact from the facility closures. So 5% to 6% organic revenue growth and another 1% or so of growth just from what was outside of that same facility group.
Kevin,那個——5% 到 6% 是有機(organic)數字。另外,從新設(de novo)設施以及我們宣布的兩項收購會有一些額外貢獻,但也會受到設施關閉的一些影響。所以是 5% 到 6% 的有機營收成長,另外大約再加 1% 左右的成長,來自不在同一設施群組內的部分。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
Okay. That's helpful. And I guess, when you think about that 5% to 6% number, is that kind of the right way to think about the growth over the -- at least the next several years given where the demand drivers are? Or is there a reason to think that number could be higher or lower in the near term?
好的。這很有幫助。我想,當你們看待這個 5% 到 6% 的數字時,考量到需求驅動因素,這是否是未來——至少未來幾年——成長的合理思考方式?或者有什麼理由認為短期內這個數字可能更高或更低?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
I think, from an organic perspective, that's our expectation going forward. And then any M&A activity, any joint ventures would provide an enhancement to that number.
我認為,從有機成長的角度來看,這就是我們對未來的預期。然後任何併購(M&A)活動、任何合資(joint ventures)都會讓這個數字有所提升。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
Okay. Great. I just wanted to confirm that. We had a lot of discussion about UHS versus Acadia. Just want to make sure that we were going -- talking about it going forward as much as we're talking about historical relative growth. Or do you still feel like that's a good number going forward?
好的。很好。我只是想確認一下。我們對 UHS 與 Acadia 做了很多討論。我只是想確保,我們談的是未來的走勢,而不只是回顧歷史上的相對成長。或者你們仍然覺得這個數字在未來是合理的?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes, we do.
是的,我們是這麼認為的。
Operator
Operator
We will take our next question from Pito Chickering with Deutsche Bank.
下一題我們請德意志銀行(Deutsche Bank)的 Pito Chickering。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
And I'll join the rest of my colleagues in welcoming you to Acadia, Debbie. Looking at the U.K., what is the ideal customer mix in that market? And I asked because you talked about the possibility of reopening facilities focused on new modalities. I just want to make sure I understand what the opportunity is.
我也跟其他同業一起歡迎你加入 Acadia,Debbie。看英國市場的話,理想的客戶組合是什麼?我之所以這樣問,是因為你提到可能會重新開放一些聚焦於新治療模式(new modalities)的設施。我只是想確保我理解其中的機會在哪裡。
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Well, the business -- Priory's business is divided into sections there with the hospital section, they have an education, they have the elderly care and then they have the adult. I think that what Priory management and the team has been focused on is making sure that we have facilities that can treat the high acuity because those are the patients that NHS frequently sends to the private sector. So I think the opportunity, as we look at those retooled beds and the beds that have come back online, are more in some of the specialty areas as well as the acute, so like child and adolescent, which they call CAMHS in the U.K., as well as eating disorder. Those are specialty areas that Priory really leads the market in. And so -- and those are also areas where NHS looks to the private sector. So those are a focus for management to try and, first of all, had beds available, but also then to improve occupancy through those specialty services.
嗯,這項業務——Priory 在那邊的業務分成幾個部分:醫院部門、教育、長者照護,然後還有成人部門。我認為 Priory 的管理層與團隊一直專注於確保我們擁有能夠治療高病情嚴重度(high acuity)患者的設施,因為 NHS 經常把這類病患送到民間(private sector)。因此我認為,當我們看這些重新整備的床位以及重新上線的床位時,機會更多在一些專科領域以及急性照護,例如兒童與青少年——在英國他們稱為 CAMHS——以及飲食失調。這些都是 Priory 在市場上真正領先的專科領域。而且——這些也同樣是 NHS 會尋求民間部門支援的領域。因此,管理層的重點是,首先要有可用床位,接著透過這些專科服務來提升入住率(occupancy)。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Got it. On the substance, like, abuse markets in the U.S., there have been some lawsuits recently about managed care sending checks directly to patients enforcing behavioral facilities to collect. Have you guys seen any impact from that?
了解。在美國的物質——例如藥物濫用——市場,最近有一些訴訟,內容是關於管理式照護把支票直接寄給病患,迫使行為健康機構自行向病患收款。你們有看到任何影響嗎?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
This is David. We have seen that. It's pretty minimal in terms of what we see there. It's mainly with 1 or 2 substance abuse facilities. But again, where we see any activity there is pretty minimal.
我是 David。我們已經看到那個了。就我們在那裡看到的內容而言,規模相當小。主要是與 1 到 2 家物質濫用治療機構有關。但再說一次,我們看到的任何活動都相當有限。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Got it. And then last question for me. Just to be very clear, from an M&A perspective, is it fair to say that you'll be putting the brakes on new announced deals until we talk again in May?
了解。那我最後一個問題。為了非常清楚,從併購(M&A)的角度來看,是否可以說在我們 5 月再次溝通之前,你們會先踩煞車、暫緩宣布新的交易?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
I don't know whether -- I wouldn't characterize it like that. I think we continue to look at opportunities, but we do want a full plan that we can roll out for the remainder of this year and next year. But we still get calls for acquisitions. But anything we do is going to be carefully evaluated. And hopefully, we'll have a very solid plan in May that will incorporate the various growth areas that we think we want to move in.
我不知道是否——我不會這樣形容。我認為我們會持續尋找機會,但我們確實希望有一個完整的計畫,能在今年剩餘時間以及明年推出並執行。不過我們仍然會接到收購方面的來電。但我們做的任何事情都會被謹慎評估。也希望我們在 5 月能有一個非常扎實的計畫,把我們認為想要推進的各個成長領域納入其中。
Operator
Operator
And we'll take our next question from Ana Gupte with SVB Leerink.
接下來我們將接聽 SVB Leerink 的 Ana Gupte 的提問。
Anagha A. Gupte - MD of Healthcare Services & Senior Research Analyst
Anagha A. Gupte - MD of Healthcare Services & Senior Research Analyst
Congrats, Debbie, and welcome to Acadia again. Just to follow up a little on some of the questions -- line of questioning before. It's helpful to hear your view of the challenges that UHS was facing and you helped address relative to where Acadia is. More broadly, would you say that as you come into this asset that your focus will be on squeezing out more value from the assets that Acadia has right now relative to the various ways of capital deployment that's been the history of this company, de novos, adding beds and M&A, where would you kind of lean here?
恭喜你,Debbie,也歡迎你再次加入 Acadia。我想稍微延續前面那一串問題的脈絡追問一下。聽到你對 UHS 當時面臨、以及你協助解決的挑戰的看法,並相對比較 Acadia 的現況,這很有幫助。更廣泛地說,你接手這項資產後,會不會把重點放在從 Acadia 目前既有資產中擠出更多價值?相較於公司過去資本配置的各種方式——新設(de novos)、增床以及併購(M&A)——你大概會比較傾向哪一邊?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Ana, I think it's going to be more appropriate and, hopefully, I'll have a lot more thorough assessment in May on those various areas. I happen to believe that there's always an ability to improve operations. I think the team here shares that view. So we're going to focus in the U.S. and the U.K. on how to improve. But also as far as strategy and areas of growth, I think I'll be better able to talk about that in May.
Ana,我認為就那些不同面向而言,等到 5 月我能做出更完整的評估後,再來談會更合適,也希望到時我能提供更深入的看法。我一向相信營運永遠有改善的空間。我認為這裡的團隊也有同樣的看法。因此我們會在美國與英國聚焦於如何改善。但至於策略與成長領域,我想我在 5 月會更有能力談得更具體。
Anagha A. Gupte - MD of Healthcare Services & Senior Research Analyst
Anagha A. Gupte - MD of Healthcare Services & Senior Research Analyst
Okay. All right. So again, just a follow-up again to the degree you can offer any color. Acadia is, as you say, pretty differentiated compared to UHS on more of a focus on substance abuse than an outpatient asset base and the like. I mean, do you see that as being better able to overcome challenges that has hit -- secularly hit the industry on payer mix, length of stay, staffing, all of that because they've already invested in CRC Health than build out some of those capabilities?
好的。好。所以再追問一次,在你能提供的範圍內,能否再多給一些說明。如你所說,Acadia 與 UHS 相比相當差異化,更多聚焦在物質濫用,而不是以門診資產為主等等。我的意思是,你是否認為這樣的定位,因為他們已經投資了 CRC Health、建立了部分能力,相較於再去建置那些能力,會更能克服產業長期(結構性)受到的挑戰,例如支付方組合(payer mix)、住院天數(length of stay)、人力配置(staffing)等各方面?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Well, I mean, I think -- before I joined Acadia and now that I'm here, I think there's a real strong track record around being able to handle the challenges around staffing and certainly with the way the portfolio and the service lines are configured across the various states. I think that we've got a lot of stability here in length of stay. And the team does a very good job, really, in all the service lines. Substance use has been very strong for Acadia. And I've been very pleased with just seeing the growth platform and the sales and marketing. I think they do some innovative things and I think it's a strong support for growth across the company.
嗯,我的意思是——在我加入 Acadia 之前,以及現在我人在這裡,我認為公司在應對人力配置相關挑戰方面有非常強的過往紀錄;而且就投資組合與各州服務線的配置方式而言也是如此。我認為我們在住院天數方面相當穩定。而團隊在所有服務線上的表現都非常出色。物質使用(治療)一直是 Acadia 的強項。我也很高興看到其成長平台,以及銷售與行銷的表現。我認為他們做了一些創新的事情,這對公司整體的成長是很強的支撐。
Operator
Operator
We'll take our next question from Gary Taylor with JPMorgan.
接下來我們將接聽 JPMorgan 的 Gary Taylor 的提問。
Gary Paul Taylor - Analyst
Gary Paul Taylor - Analyst
Just a couple of quick clarifications. On the 700 beds, I presume majority of those are U.S., but do you have a breakdown for us on the 2019 bed addition?
我有幾個快速釐清。關於那 700 張床位,我推測大多數在美國,但你們能否提供 2019 年新增床位的拆分給我們?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes. Gary, this is David. More than 600 of those beds are in the U.S. The opportunity in the U.K. is, of course, mostly related to the occupancy. We will still add just under 100 beds in the U.K., but think the occupancy is the key for the U.K. for this year. And it's a great number for the U.S. The more than 600 beds does include the 2 that we have already opened in the first quarter. But it's a great number for the remainder of the year to our existing facilities.
可以。Gary,我是 David。其中超過 600 張床位在美國。英國的機會當然主要與入住率(occupancy)有關。我們在英國仍會新增不到 100 張床位,但我們認為今年英國的關鍵在於入住率。而對美國來說,這是個很好的數字。超過 600 張床位也包含我們在第一季已經開出的 2 家(設施)。但就今年剩餘時間而言,對我們既有設施來說,這仍是個很好的新增數字。
Gary Paul Taylor - Analyst
Gary Paul Taylor - Analyst
Got you. And the 16% U.K. margin target, is that for the full year or the second half of '19?
了解。那英國 16% 的利潤率目標,是指全年,還是 2019 年下半年?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
That's for the second half of 2019, Gary.
那是 2019 年下半年,Gary。
Gary Paul Taylor - Analyst
Gary Paul Taylor - Analyst
Got you. And then I was just hoping for -- I was hoping for cash from ops and CapEx guidance, but if you can't give that, maybe just talk qualitatively or directionally about CapEx with the bed growth coming down a little bit and none of that being new facility building. I would imagine the CapEx would come down year-over-year. But any help on those 2 metrics?
了解。另外我原本希望能取得營運現金流與資本支出(CapEx)的指引;如果你們無法提供,也許可以用定性或方向性的方式談談:隨著床位成長稍微放緩,而且也沒有新建設施的建造,我想像資本支出應該會年減。我想資本支出應該會年減。這兩個指標能否提供一些協助?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Sure. We are forecasting 2019 to be similar to 2018. And the operating cash flows, we do see in a range of $400 million to $425 million. The maintenance CapEx should be similar to 2018 as well. It's around $74 million in 2018. We see that at that same level in 2019. And the expansion CapEx is similar to 2018 as well. We spent $286 million in 2018 and see a range of $275 million to $300 million in 2019. You can't exactly look at the number of beds that are added in a year and predict the expansion CapEx just because a lot of the activity starts well in advance of opening a bed. And so a lot of what we would be spending in 2019 would not only relate to 2019 beds, but also to what's in the works for 2020. So it's a very similar year in terms of the cash flows and the use of the cash flows as -- in '19 as it was in '18.
當然。我們預估 2019 年會與 2018 年相近。營運現金流方面,我們預期落在 4 億至 4.25 億美元的區間。維護性資本支出也應與 2018 年相近。2018 年約為 7,400 萬美元。我們預期 2019 年也會在相同水準。擴張性資本支出也與 2018 年相近。我們 2018 年支出 2.86 億美元,2019 年預期在 2.75 億至 3 億美元的區間。你不能只看一年新增的床位數就去推估擴張性資本支出,因為很多活動在床位開出之前很久就已經開始。因此我們在 2019 年的很多支出,不僅與 2019 年的床位相關,也與 2020 年正在進行中的項目相關。所以就現金流以及現金流的使用而言,2019 年與 2018 年非常相似。
Gary Paul Taylor - Analyst
Gary Paul Taylor - Analyst
Got you. And then just a last quick one for Deb. When we think about this review that you're doing and going to present the conclusions of in May, can you -- is that characterized primarily as an operational and strategic review? Or is it as broad as including strategic alternatives? Obviously, there was a lot of rumors in the fall that the company was considering a potential buyout. I don't think ever publicly, Acadia had commented on it. But is this -- does this review you're doing potentially is why it is including strategic alternatives or it would be more operational in nature or not care to refine the characterization?
了解。最後再給 Deb 一個快速問題。當我們思考你正在進行、並將在 5 月提出結論的這項檢視(review)時,你能否說明——它主要被界定為營運與策略檢視嗎?還是範圍廣到包含策略替代方案(strategic alternatives)?顯然去年秋天有很多傳聞說公司在考慮可能的收購(buyout)。我想 Acadia 從未公開評論過。但你正在做的這個檢視,是否可能包含策略替代方案?還是會更偏向營運性質?或者你不方便進一步界定?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
I think I would say that it's going to be very comprehensive.
我想我會說,這將會非常全面。
Operator
Operator
And we'll take our next question from Peter Costa with Wells Fargo.
接下來我們請 Wells Fargo 的 Peter Costa 提問。
Peter Heinz Costa - MD and Senior Analyst
Peter Heinz Costa - MD and Senior Analyst
And congrats on the new role. Two questions here. The first one, really, Acadia had a number of issues over the last couple of years and bad press. And presumably, you saw all that before you came aboard. And presumably, one of the first things you did was look at the operational controls and compliance that the company has. And how do you feel about that compared to where you came from?
恭喜你擔任新職務。我這裡有兩個問題。第一個問題是,Acadia 在過去幾年出現了不少問題,也有一些負面新聞。我想你在加入之前應該都看過。我猜想你做的第一件事之一,就是檢視公司現有的營運控制與法遵(合規)機制。你覺得這些方面與你之前任職的公司相比如何?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
I think it's very strong here, the compliance and quality effort. Acadia has a Corporate Medical Director who's very focused on supporting quality at the facility. There's a very robust team that supports the facilities. So I've been very pleased with what I've seen. I think there's always room for improvement. We treat very ill patients that are acute. And what I've seen at -- on the Acadia side is we're working really hard to make sure we're proactive and that we evaluate the facilities and make sure that we keep any incidents to a minimum. But I think the compliance and quality team is strong.
我認為這裡的合規與品質工作非常強。Acadia 有一位企業醫療總監,非常專注於支持各院所的品質。也有一個非常健全的團隊在支援各院所。所以我對目前看到的情況非常滿意。我認為永遠都有改進空間。我們治療的是病情非常嚴重、屬於急性期的病患。而我在 Acadia 這邊看到的是,我們非常努力確保能夠主動預防,並評估各院所,確保把任何事件降到最低。但我認為合規與品質團隊很強。
Peter Heinz Costa - MD and Senior Analyst
Peter Heinz Costa - MD and Senior Analyst
So we shouldn't be thinking about a big spend on that going forward after your review is done. Is that the way for me to think about that answer?
所以在你完成檢視之後,我們不需要預期未來在這方面會有一筆很大的支出。我可以這樣理解你的回答嗎?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
I think -- again, I'm assessing everything, so I don't really want to comment on where we're going to end up with that. But I do think that it's a very solid process in place now. But one of the things I will look at is if there are other things we need to be doing.
我想——再次強調,我正在評估所有事情,所以我不太想評論我們最後會落在什麼結果。但我確實認為目前已經有一套非常扎實的流程。不過我會檢視的一件事是,是否還有其他我們需要做的事情。
Peter Heinz Costa - MD and Senior Analyst
Peter Heinz Costa - MD and Senior Analyst
Okay. And then my second question is just, really, last year, we saw a couple of spending bills to increase opioid funding. It's not clear we've seen a lot of that come through, although perhaps we have if we look at your performance relative to Universal. You're a strong on the same store growth. And perhaps, it's from your more outpatient, more substance abuse focus than they have. Is it the opioid spending money that's keeping your growth rate a little bit higher? Or is that still yet to come? Can you kind of comment on where that opioid money is today?
好的。第二個問題是,去年我們看到幾項支出法案要增加阿片類藥物(opioid)相關資金。目前還不清楚這些資金是否已大量到位,雖然如果看你們相對於 Universal 的表現,也許已經反映出來。你們同店成長很強。也許是因為你們比他們更偏門診、也更聚焦於物質濫用治療。是阿片類資金支出讓你們的成長率略高一些嗎?還是說那仍有待後續到位?你能否談談目前這些阿片類資金的狀況?
William Brent Turner - President
William Brent Turner - President
Yes. Peter, this is Brent Turner. I'd say a couple of things. Again as David pointed out earlier, the bed additions and the service line diversity have really fueled the Acadia same facility growth along with our comprehensive treatment centers. I'd say the demand has continued to outpace supply in the opioid treatment market. There's been recent bills over the last few years, most recently in the fall, the SUPPORT Act, which will continue to bring benefit to the outpatient treatment, but also inpatient needs of substance abuse disorders that Medicaid will cover that, where they haven't been covering it under the IMD limitation. So what I'd say is there is good demand, but there's definitely future funding that will benefit providers. In fact, the bill I just referenced doesn't go effective until October 1 of this year. So we're continuing to focus on trying to make sure that the headline positivity around opioid coverage, the money actually finds its way to the patients. That's the ultimate goal here. So I think we got some positives there.
是的。Peter,我是 Brent Turner。我想說幾點。如同 David 先前提到的,新增床位與服務線多元化,再加上我們的綜合治療中心(comprehensive treatment centers),確實推動了 Acadia 的同院所成長。我會說,在阿片類治療市場,需求持續超過供給。過去幾年有一些新法案,最近一次是在秋季通過的 SUPPORT Act,將持續為門診治療帶來助益,也會滿足物質使用障礙的住院需求;Medicaid 也將開始涵蓋這些需求,而過去在 IMD 限制下並未涵蓋。所以我要說的是,需求面良好,但未來也確實會有資金到位,讓服務提供者受益。事實上,我剛提到的那項法案要到今年 10 月 1 日才生效。因此我們會持續專注,確保關於阿片類保障的正面頭條,資金能真正流向病患。這才是最終目標。所以我認為這方面有一些正面因素。
Peter Heinz Costa - MD and Senior Analyst
Peter Heinz Costa - MD and Senior Analyst
Have you able to track that in any ways, so you can sort of share with us some progress on that?
你們是否能以任何方式追蹤這些資金的落地情況,讓你們可以和我們分享一些進展?
William Brent Turner - President
William Brent Turner - President
Well you might remember, over the last 12 months, we've seen a couple of states that historically did not cover the outpatient opioid treatment for their Medicaid population. Due to some of the Cures monies that came to the state, they actually moved and began to cover that. And again, this is just a huge position change because Medicaid beneficiary has financial challenges, and these individuals were having to pay for that treatment themselves. And it was unbelievably impressive that they were doing that. Now they're able to access their treatment through the Medicaid plans. So I think those are a couple of examples and I think we will see more of that as we go forward.
嗯,你可能記得,在過去 12 個月,我們看到有幾個州,過去對其 Medicaid 人口並不涵蓋門診阿片類治療。由於一些 Cures 資金撥給了州政府,他們實際上做出調整並開始提供這項涵蓋。而且再次強調,這是一個非常重大的立場轉變,因為 Medicaid 受益人有財務上的挑戰,這些人過去必須自掏腰包支付治療費用。他們能做到這點其實非常令人敬佩。現在他們可以透過 Medicaid 計畫取得治療。所以我認為這是幾個例子,我也認為未來我們會看到更多這樣的情況。
Operator
Operator
We will take our next question -- follow-up from John Ransom with Raymond James.
接下來我們請 Raymond James 的 John Ransom 進行追問。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
This is taking in after all these good strategic questions. But David, I was just looking for a little bit of help as we think about the EBITDA progression through the year. And also could you -- you mentioned a number of things. Is there any way you could maybe more precisely size some of the contributors of the 1Q run rate followed into the next 3 quarters?
在聽完這些很好的策略性問題之後,我這個問題可能比較偏細節。但 David,我想請你協助我們理解全年 EBITDA 的走勢。另外你提到不少事項。你是否能更精確地量化一下,第一季的 run rate 延伸到接下來三個季度時,各項貢獻因素的規模?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes. Sure, John. The items I mentioned earlier around the U.K. run rate, the improvement in the U.S. operations from the bed growth as well as the nonoperating expenses, happy to clarify and provide more detail there around some of those items. The -- in the U.S., we do see the first quarter EBITDA number reflecting the de novo losses as well as the facility closures. Does cause to the U.S. EBITDA to be somewhat flat year-over-year. And then as we move ahead into the remainder of the year, there's significant build in the EBITDA, and we see EBITDA growth there of around $15 million coming off of the first quarter into the run rate in for the last 9 months of the year. In the U.K., the year-over-year impact of the margin comparing the first quarter of '19 to the first quarter of 2018 has about a $7 million to $8 million year-over-year impact just on the first quarter number. And that's where, as we see some of the initiatives, the retooling beds, the occupancy improvement, the pricing increases and other matters, we think that by the second quarter, the year-over-year will be somewhat flat with the growth opportunity in the U.K. in the second half of the year.
可以。當然可以,John。我先前提到的幾個項目,包括英國的 run rate、美國營運因床位成長帶來的改善,以及非營運費用,我很樂意在這些項目上再釐清並提供更多細節。在美國方面,我們確實看到第一季的 EBITDA 數字反映了新設(de novo)據點的虧損以及院所關閉的影響。這使得美國 EBITDA 年對年相對持平。接著展望今年剩餘期間,EBITDA 會有顯著的提升;我們看到從第一季到今年後 9 個月的 run rate,EBITDA 成長約 1,500 萬美元。在英國方面,若比較 2019 年第一季與 2018 年第一季的利潤率,僅第一季這個數字的年對年影響約為 700 萬到 800 萬美元。而隨著我們推動一些措施——床位重新配置(retooling beds)、入住率改善、價格上調及其他事項——我們認為到第二季,英國的年對年表現會大致持平,而英國在下半年將有成長機會。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
So if you had to say 1, 2, 3, what are the top 3 EBITDA contributors if you look at the 4Q versus, say, the 1Q? What are the 3 biggest things that will change?
所以如果要你用 1、2、3 來說,若比較第四季與第一季,EBITDA 的前三大貢獻因素是什麼?會改變的三件最大事情是什麼?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Well, going from the fourth quarter to the first quarter, of course, you have -- just every year, we have the resetting of payroll taxes, the fewer days in the first quarter, that has an impact, fourth quarter to first quarter. And that's about an $8 million or $9 million impact that we see every first quarter. So that would be the key factor just going from the fourth quarter to the first quarter.
嗯,從第四季到第一季,當然你會看到——每一年都一樣——薪資稅的重置,以及第一季天數較少,這些都會造成從第四季到第一季的影響。我們每個第一季都會看到大約 800 萬到 900 萬美元的影響。所以這會是從第四季到第一季最關鍵的因素。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
So -- I'm sorry, I was saying, like, first quarter '19 to fourth quarter '19, what are -- in your model, if you look at 4Q EBITDA, what's the -- is it the -- I guess, just the improvement in the U.S. as the biggest factor and just an improved census. Is that really the biggest as you fill up the de novo beds? Is that really the #1 driver?
所以——抱歉,我剛剛是說,像是 2019 年第一季到 2019 年第四季,在你的模型裡,如果你看 4Q EBITDA,最大的因素是什麼——是它——我想,主要因素就是美國的改善,以及入住人數(census)的提升。當你把新設(de novo)的床位逐步填滿時,這真的是最大的因素嗎?這真的是第一大驅動因素嗎?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes, #1 factor, I'm sorry, first quarter of '19 to the run rate by the end of the '19, absolutely, the U.S. filling up the beds that have been added in 2018. Seeing the improvement in the de novo beds. And then also the contribution from 2019 new beds, the U.S. improvement would be #1. And secondly, just in the U.K., we do see -- while it's a headwind in the first quarter, we do see that improvement opportunity in the second half of the year.
是的,第一大因素。抱歉,2019 年第一季到 2019 年底的運行水準(run rate),絕對是美國把 2018 年新增的床位逐步填滿。看到新設(de novo)床位的改善。另外還有 2019 年新增床位的貢獻,美國的改善會是第一位。第二,在英國方面,我們確實看到——雖然第一季是逆風,但我們確實看到下半年有改善的機會。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
And how much of the U.K. is just the pricing?
那英國的部分有多少只是定價(pricing)因素?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Well, we don't really provide that detail on the pricing. The pricing does happen for the most part for much of the revenue in April, so that's why it will be a positive in the second quarter. Some -- a lot of the cost increases do happen more throughout the year. So that's one reason why the second quarter does get a little bit better.
嗯,我們不太提供定價方面的細節。定價調整大多在 4 月發生,涵蓋了相當大部分的營收,所以這也是為什麼第二季會是正面因素。有些——很多成本上升則更分散地發生在全年各個時點。所以這也是第二季會稍微好轉的一個原因。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
And then lastly, for Deb, when you kind of wrap up your review, how do you guys plan to roll this message out to the market? Is there going to be a call, a presentation? What are you planning on? And is it going to be later in the month, middle of the month or we're not just down the road enough to have to -- have that figured out?
最後一題給 Deb,當你把檢視工作告一段落時,你們打算如何把這個訊息對市場發布?會有電話會議、簡報嗎?你們打算怎麼做?會是在本月稍晚、月中,還是我們目前還沒有走到那一步——還沒把這些細節定下來?
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
I don't think we're down the road enough to have a detail about how and when, but I'm working as -- very diligently and as quickly as we can, so we can get a plan to articulate to investors and also to direct the team around our strategies.
我想我們目前還沒有走到能提供「如何」以及「何時」的細節,但我正——非常勤勉、也盡可能快速地推進,讓我們能制定一個計畫,向投資人清楚說明,也引導團隊圍繞我們的策略行動。
Operator
Operator
And we'll take our final question from Whit Mayo.
接下來我們的最後一個問題來自 Whit Mayo。
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
I just need to go back to the U.K. just for a second. When looking at the last 2 years, the same store EBITDA on a constant currency basis has declined for 9% -- has declined about 9%. It's fell 18% in the second half of the year. I think you stated you believe the margins are expected to be around 15% in the first quarter, which implies another decline of 15% on a same store basis. And then I'm just really struggling to visualize how we get an abrupt reversal in this trend line to flatten out and turn positive. So David, is there anything else to say to give us increased confidence that given that trajectory that it's been on that it can actually reverse itself from some of these initiatives?
我想再回到英國的部分一下。看過去兩年,以固定匯率(constant currency)計算的同店 EBITDA 已經下滑 9%——大約下滑了 9%。在下半年下滑了 18%。我記得你提到你認為第一季的利潤率(margins)預期大約在 15% 左右,這意味著同店基礎上又會再下滑 15%。我真的很難想像,我們要如何讓這條趨勢線突然反轉,先趨於持平再轉正。所以 David,還有沒有其他可以說的,讓我們更有信心:以目前這樣的軌跡,這些措施真的能讓它扭轉?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes. And Whit, maybe I'll start by just saying it's not necessarily a reversal back to the previous margins, but the decline that we saw starting in the third quarter will anniversary in the second half of 2019. And we do see improvement in the margin from some of the initiatives that we've mentioned. The -- there's a number of items that affected the margin decline where we saw employee -- labor cost increases, the impact of the beds that have been offline for retooling, the cost increases haven't always been covered by the pricing increases. And we're more positive on that for this year. So I think that just the progress that we see and the beds that have been retooled, seeing a stronger occupancy and margin from those facilities, the pricing increases that, hopefully, will be more appropriate based on the cost increases and just getting past the first half comparison from 2018.
有的。Whit,也許我先說,這不一定是回到先前的利潤率水準的「反轉」,但我們從第三季開始看到的下滑,會在 2019 年下半年進入同比基期(anniversary)。而且我們確實看到,來自我們提到的一些措施,利潤率會有所改善。——有多項因素影響了利潤率下滑:我們看到員工——人力成本上升、因重新配置(retooling)而暫停使用的床位所帶來的影響、成本上升並不總是能被價格上調所覆蓋。而對於今年,我們在這方面更為正面。所以我認為,從我們看到的進展、已完成重新配置的床位、這些機構更強的入住率與利潤率表現、以及(希望)能更貼近成本上升幅度的價格上調,再加上度過 2018 年上半年的比較基期,這些都會帶來改善。
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care
Okay. And then I'm sorry, 2 quick clarification questions. On the acquisitions, I think you said there was $40 million of annualized EBITDA you thought in the first quarter. Any way to put up a margin and an EBITDA number on that just so we understand the tailwinds this year? And then are there any other implications about the lab business in West Virginia? Anything to sort of consider headwinds or tailwinds?
好的。然後抱歉,兩個很快的釐清問題。關於併購,我想你說第一季你認為有 4,000 萬美元的年化 EBITDA。能否提供一下那部分的利潤率和 EBITDA 數字,讓我們了解今年的順風有多大?另外,西維吉尼亞州的實驗室(lab)業務還有其他影響嗎?有沒有什麼需要考量的逆風或順風?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes. Let me clarify for the acquisitions. The combined purchase price for those 2 acquisitions was approximately $40 million. The revenue and EBITDA associated with those, around $20 million of revenue and $3.5 million to $4 million of trailing EBITDA. The -- with respect to your question on the lab, we do think West Virginia was unique. The -- most of our payers and states pay a bundled rate for the medication-assisted treatment. And so West Virginia was a pretty unique situation in terms of there being a separate billing for the lab services.
好的。我先釐清併購部分。那兩筆併購的合計收購價格約為 4,000 萬美元。與之相關的營收與 EBITDA,大約是 2,000 萬美元營收,以及 350 萬到 400 萬美元的過去十二個月(trailing)EBITDA。——至於你問到實驗室的部分,我們確實認為西維吉尼亞州是比較特殊的情況。——我們大多數的付款方(payers)與州政府,對藥物輔助治療(medication-assisted treatment)採用打包費率(bundled rate)。因此,西維吉尼亞州在實驗室服務可以單獨計費這點上,是相當獨特的情況。
Operator
Operator
At this time, I would like to turn the conference back to Debbie for any closing or additional remarks.
此時,我想把電話會議交回 Debbie,請她做任何結語或補充說明。
Debra K. Osteen - CEO & Director
Debra K. Osteen - CEO & Director
Thank you. Thanks again for being with us today and for the welcome. As the new leader of Acadia Healthcare, I'm very pleased with what I've seen these past few months. The company has dedicated employees and clinicians and also quality treatment programs, which, I believe, will be a solid foundation for the future growth and success of Acadia. If you have additional questions today, please do not hesitate to contact directly -- us directly, and have a good day. Thank you.
謝謝。再次感謝今天與會,也謝謝大家的歡迎。作為 Acadia Healthcare 的新領導者,我對過去幾個月所看到的情況感到非常滿意。公司擁有敬業的員工與臨床人員,以及高品質的治療方案;我相信這將成為 Acadia 未來成長與成功的堅實基礎。如果你今天還有其他問題,請不要猶豫,直接——直接與我們聯繫,祝各位有美好的一天。謝謝。
Operator
Operator
Ladies and gentlemen, this does conclude today's presentation. We thank you for your participation. You may now disconnect.
各位女士、先生,今天的簡報到此結束。感謝各位的參與。您現在可以掛線。